Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 29, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

648

[Lupus nephritis].

Quentin Raimbourg1, Éric Daugas1

  • 1Service de néphrologie, hôpital Bichat, 46, rue Henri-Huchard, 75877 Paris cedex 18, France; Université Paris Diderot, 5, rue Thomas-Mann, 75013 Paris, France; Inserm U1149, Département hospitalo-universitaire (DHU) Fibrosis-Inflammation-Remodeling (FIRE), 16, rue Henri Huchard, 75890 Paris cedex 18, France.

Nephrologie & Therapeutique
|February 11, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease.

Kidney international·2026
Same author

Anti-CD38 Therapy With Daratumumab in High-Risk IgA Nephropathy.

Kidney international reports·2026
Same author

Kidney biopsy during pregnancy: indications, complications, results and therapeutic impact.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

The Case | Febrile pancytopenia with mixed cryoglobulinemia and glomerulonephritis in a traveler.

Kidney international·2026
Same author

Effect of Steroids on Anti-nephrin Autoantibodies and B cells in Minimal Change Disease.

Kidney international reports·2026
Same author

Levels of circulating kidney injury markers and IL-10 identify non-critically ill patients with COVID-19 at risk of death.

JCI insight·2026

Systemic lupus erythematosus can cause lupus nephritis, a severe kidney condition. Treatment focuses on remission and relapse prevention using immunosuppressants like steroids, cyclophosphamide, and mycophenolate, balancing efficacy with side effects.

Area of Science:

  • Nephrology
  • Immunology
  • Rheumatology

Background:

  • Systemic lupus erythematosus (SLE) is an autoimmune disease impacting multiple organs, notably the kidneys, leading to lupus nephritis.
  • Lupus nephritis affects 10-40% of SLE patients, often presenting with proteinuria, necessitating renal biopsy for severity assessment.
  • Severe lupus nephritis classes (III, IV-A) are linked to poor renal prognosis and increased mortality.

Purpose of the Study:

  • To outline current therapeutic strategies for lupus nephritis, emphasizing remission induction and relapse prevention.
  • To discuss the management of different lupus nephritis classes, including pure membranous lupus nephritis (class V).
  • To address the considerations for pregnancy and renal replacement therapy in lupus nephritis patients.

Main Methods:

Keywords:
CyclophosphamideGlomérulonéphriteGrossesse à risqueInduction therapyLupusLupus nephritisMaintenance therapyMycophénolate mofétilPregnancyRein

More Related Videos

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.6K
Analysis of Fecal Microbiota Dynamics in Lupus-Prone Mice Using a Simple, Cost-Effective DNA Isolation Method
05:28

Analysis of Fecal Microbiota Dynamics in Lupus-Prone Mice Using a Simple, Cost-Effective DNA Isolation Method

Published on: May 2, 2022

2.5K

Related Experiment Videos

Last Updated: Jan 29, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

648
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.6K
Analysis of Fecal Microbiota Dynamics in Lupus-Prone Mice Using a Simple, Cost-Effective DNA Isolation Method
05:28

Analysis of Fecal Microbiota Dynamics in Lupus-Prone Mice Using a Simple, Cost-Effective DNA Isolation Method

Published on: May 2, 2022

2.5K
  • Review of established induction therapies, primarily high-dose steroids and cyclophosphamide.
  • Evaluation of mycophenolate as an alternative to cyclophosphamide to mitigate side effects like infertility.
  • Assessment of maintenance therapies including mycophenolate and azathioprine for relapse prevention.

Main Results:

  • High-dose steroids and cyclophosphamide are the most experienced induction therapy, with mycophenolate as an alternative.
  • Mycophenolate is more effective for maintenance therapy than azathioprine but carries a high teratogenicity risk.
  • Withdrawal of maintenance therapy is possible after 2-3 years without high relapse risk factors, though relapse risk assessment needs improvement.
  • Pure class V lupus nephritis requires specific therapies, with optimal immunosuppressive strategies still under investigation.
  • Pregnancy can be managed safely with close monitoring, and renal replacement therapy/transplantation are viable options.

Conclusions:

  • Treatment of lupus nephritis involves balancing efficacy with adverse effects, particularly infertility and teratogenicity.
  • Personalized therapeutic approaches are needed, especially for class V lupus nephritis and during pregnancy.
  • Renal transplantation offers the best long-term option for end-stage renal disease in lupus nephritis patients.